News

New Study Reveals Ozempic and Weight-Loss Drugs May Reduce Risk of Obesity-Linked Cancers
A recent study reveals that weight-loss medications such as Ozempic may reduce the risk of obesity-related cancers, including ...
The Cigna Group (CI): A Bull Case Theory
We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares’ Substack. In this article, we will summarize the ...
Can this under-the-radar company cash in on the $150 bn weight-loss drug boom?
Onesource Specialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with ...
BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025
BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies ...
This Sleazy GLP-1 Prescription Site Is Using Deepfaked "Before-and-After" Photos of Fake Patients, and Running Ads Showing AI-Generated Ozempic Boxes
MEDVi, an online hub for GLP-1 drugs, wants you to know that it's "serious" about helping you lose weight. According to its ...
The American Journal of Managed Care13h
Contributor: Yearly Trends in Coverage Rates for GLP-1 RAs in Weight Loss
Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...
Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.
After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of ...
Jack Mosley: ‘The obesity crisis is not a collapse in willpower’
The late Dr Michael Mosley was the nation’s trusted authority on how to improve our health. Now his son Jack is continuing ...
I lost four stone in four months on Mounjaro - but then it made me go bald and almost killed me
Aimee Chapman, 34, from Southampton, was admitted to intensive care last summer after developing liver failure and a hole in ...
BioAge Labs, Inc.: BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor ...